Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Sponsor: University of Illinois at Chicago
Summary
The study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant (HSCT). The primary objective of the study is to determine the engraftment at Day +60 following HLA-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents and low-dose total body irradiation (TBI) for conditioning and post-transplant cyclophosphamide in patients with sickle cell disease.
Official title: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Key Details
Gender
All
Age Range
16 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2017-03-20
Completion Date
2026-05
Last Updated
2026-01-26
Healthy Volunteers
No
Conditions
Interventions
ATG
0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
fludarabine
30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
cyclophosphamide
14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
Total body irradiation
3 Gy on day -1
Stem cell infusion
Stem cell product infused according to BMT unit policy on day 0.
Sirolimus
loading dose of 15 mg followed by 5 mg per day on day +5
mycophenolate mofetil
1 g every 8 h (until day 35) will be started on day 5
Locations (1)
University of Illinois at Chicago
Chicago, Illinois, United States